IODINE I 131 TOSITUMOMAB definition

IODINE I 131 TOSITUMOMAB means any therapeutic, prophylactic or palliative product containing or comprising the composition of matter conjugated with 131Iodine that was one of the active agents tested in Corixa's clinical trial with Protocol No. RIT-II-004 as referred to in that Protocol as [*] anti CD20 murine monoclonal antibody.
Sample 1Sample 2Sample 3
IODINE I 131 TOSITUMOMAB means a therapeutic, prophylactic or palliative product that (a) contains or comprises the IgG(2a) anti-CD20 murine monoclonal antibody conjugated with (131)Iodine that was one of the active agents tested in Corixa's clinical trials with Protocol Nos. RIT-II-004 and CP-97-012, (b) is supplied at [*] protein and activity concentrations of (i) [*] mg/mL and [*] mCi/mL (at calibration), respectively, for the dosimetric dosage form and (ii) [*] mg/mL and [*] mCi/mL (at calibration), respectively, for the therapeutic dosage form, and (c) has been formulated with [*] (or another formulation agreed upon in writing by the Parties). Except as otherwise specified in this Agreement, Iodine I 131 Tositumomab shall mean only filled material.
Sample 1Sample 2
IODINE I 131 TOSITUMOMAB means any therapeutic, prophylactic or palliative product [*] or [*] the [*] of [*] conjugated with 131Iodine that was one of the active agents tested in Corixa's clinical trial with Protocol No. RIT-II-004 as referred to in that Protocol as [*] anti CD20 murine monoclonal antibody.
Sample 1

More Definitions of IODINE I 131 TOSITUMOMAB

IODINE I 131 TOSITUMOMAB means a [*] product that contains or comprises the [*] monoclonal antibody, as sublicensed to Coulter pursuant to the terms and conditions of the Dana-Farber Agrexxxxxx and including all improvements thereto made bx xx xx xxxalf of the Sellers prior to the Closing, conjugated with (131)Iodine. -7- *CONFIDENTIAL TREATMENT REQUESTED.
Sample 1
IODINE I 131 TOSITUMOMAB means any [*] product [*] conjugated with 131Iodine [*] murine monoclonal antibody.
Sample 1
IODINE I 131 TOSITUMOMAB means any [*] product [*] with 131Iodine that was [*] anti CD20 murine monoclonal antibody.
Sample 1

Related to IODINE I 131 TOSITUMOMAB

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Phase III Clinical Study means a pivotal Clinical Study, the results of which could be used to establish safety and efficacy of a Licensed Product in the Field as a basis for Regulatory Approval or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent.

  • Assay means a laboratory analysis of Crude Petroleum to include the following: A.P.I. Gravity, Reid vapor pressure, composition, pour point, water and sediment content, sulfur content, viscosity, distillation, hydrogen sulfide, flash/boiling point and other characteristics as may be required by Carrier.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Phase II Clinical Trial means a study in humans of the safety, dose ranging and efficacy of a product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial or to file for accelerated approval, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(b) or its foreign equivalents.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.